Top Markets
#1 Status Status +24.09%
#2 Ontology Gas Ontology Gas +22.68%
#3 EXOD EXOD +22.08%
#4 ETHGas ETHGas +17.93%
#5 The Black Bull The Black Bull +15.99%
#6 Fake World Assets Fake World Assets +11.81%
#7 aelf aelf +10.18%
#8 Derive Derive +8.58%
#9 Gas Gas +8.36%
#10 Tornado Cash Tornado Cash +7.15%
Coin of the day
Status Status
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Classificação em ações #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Preço da ação
$9.81
Última sincronização: 2025-03-18
Valor de mercado
$48.68M
Variação (1 dia)
1.55%
Variação (1 ano)
0.00%
País
US
Negociar AlloVir, Inc. (ALVR)

Categoria

Healthcare
Receita da AlloVir, Inc. (ALVR)
Receita em Jun 2026 TTM: 0.00
De acordo com os últimos relatórios financeiros da AlloVir, Inc., a receita atual da empresa (TTM) é 0.00. Em 2023, a empresa obteve uma receita de 0.00 igual a a receita do ano 2022, que foi de 0.00. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da AlloVir, Inc. de 2018 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $165.00K -85.46%
2018 $1.14M 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US